Literature DB >> 24961642

Discovery and SAR of a novel series of metabotropic glutamate receptor 5 positive allosteric modulators with high ligand efficiency.

Mark Turlington1, Meredith J Noetzel2, Thomas M Bridges2, Paige N Vinson2, Thomas Steckler3, Hilde Lavreysen3, Claire Mackie4, José M Bartolomé-Nebreda5, Susana Conde-Ceide5, Han Min Tong5, Gregor J Macdonald3, J Scott Daniels2, Carrie K Jones2, Colleen M Niswender2, P Jeffrey Conn2, Craig W Lindsley1, Shaun R Stauffer6.   

Abstract

We report the optimization of a series of novel metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs) from a 5,6-bicyclic class of dihydropyrazolo[1,5-a]pyridin-4(5H)-ones containing a phenoxymethyl linker. Studies focused on a survey of non-amide containing hydrogen bond accepting (HBA) pharmacophore replacements. A highly potent and selective PAM, 2-(phenoxymethyl)-6,7-dihydropyrazolo[1,5-a]pyridin-4(5H)-one (11, VU0462054), bearing a simple ketone moiety, was identified (LE=0.52, LELP=3.2). In addition, hydroxyl, difluoro, ether, and amino variations were examined. Despite promising lead properties and exploration of alternative core heterocycles, linkers, and ketone replacements, oxidative metabolism and in vivo clearance remained problematic for the series.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Metabotropic glutamate receptor 5 (mGlu(5)); Positive allosteric modulator (PAM)

Mesh:

Substances:

Year:  2014        PMID: 24961642      PMCID: PMC4234308          DOI: 10.1016/j.bmcl.2014.04.087

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  22 in total

Review 1.  Discovery of positive allosteric modulators of metabotropic glutamate receptor subtype 5 (mGluR5).

Authors:  David L Williams; Craig W Lindsley
Journal:  Curr Top Med Chem       Date:  2005       Impact factor: 3.295

Review 2.  The influence of lead discovery strategies on the properties of drug candidates.

Authors:  György M Keserü; Gergely M Makara
Journal:  Nat Rev Drug Discov       Date:  2009-03       Impact factor: 84.694

3.  Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity.

Authors:  Jerri M Rook; Meredith J Noetzel; Wendy A Pouliot; Thomas M Bridges; Paige N Vinson; Hyekyung P Cho; Ya Zhou; Rocco D Gogliotti; Jason T Manka; Karen J Gregory; Shaun R Stauffer; F Edward Dudek; Zixiu Xiang; Colleen M Niswender; J Scott Daniels; Carrie K Jones; Craig W Lindsley; P Jeffrey Conn
Journal:  Biol Psychiatry       Date:  2012-11-07       Impact factor: 13.382

4.  Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism.

Authors:  Thomas M Bridges; Jerri M Rook; Meredith J Noetzel; Ryan D Morrison; Ya Zhou; Rocco D Gogliotti; Paige N Vinson; Zixiu Xiang; Carrie K Jones; Colleen M Niswender; Craig W Lindsley; Shaun R Stauffer; P Jeffrey Conn; J Scott Daniels
Journal:  Drug Metab Dispos       Date:  2013-07-02       Impact factor: 3.922

5.  A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models.

Authors:  Gene G Kinney; Julie A O'Brien; Wei Lemaire; Maryann Burno; Denise J Bickel; Michelle K Clements; Tsing-Bau Chen; David D Wisnoski; Craig W Lindsley; Philip R Tiller; Sheri Smith; Marlene A Jacobson; Cyrille Sur; Mark E Duggan; Douglas J Pettibone; P Jeffrey Conn; David L Williams
Journal:  J Pharmacol Exp Ther       Date:  2004-12-17       Impact factor: 4.030

6.  Preclinical profile of a novel metabotropic glutamate receptor 5 positive allosteric modulator.

Authors:  Nathan Spear; Reto A Gadient; Deidre E Wilkins; MyLinh Do; Jeffrey S Smith; Kim L Zeller; Patricia Schroeder; Minli Zhang; Jalaj Arora; Vijay Chhajlani
Journal:  Eur J Pharmacol       Date:  2011-02-16       Impact factor: 4.432

7.  In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat.

Authors:  Gary Gilmour; Lisa M Broad; Keith A Wafford; Thomas Britton; Ellen M Colvin; Adam Fivush; Francois Gastambide; Brian Getman; Beverly A Heinz; Andrew P McCarthy; Lourdes Prieto; Elaine Shanks; Janice W Smith; Lorena Taboada; Dale M Edgar; Mark D Tricklebank
Journal:  Neuropharmacology       Date:  2012-08-01       Impact factor: 5.250

8.  N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement.

Authors:  K J Gregory; E J Herman; A J Ramsey; A S Hammond; N E Byun; S R Stauffer; J T Manka; S Jadhav; T M Bridges; C D Weaver; C M Niswender; T Steckler; W H Drinkenburg; A Ahnaou; H Lavreysen; G J Macdonald; J M Bartolomé; C Mackie; B J Hrupka; M G Caron; T L Daigle; C W Lindsley; P J Conn; C K Jones
Journal:  J Pharmacol Exp Ther       Date:  2013-08-21       Impact factor: 4.030

9.  Optimization of an ether series of mGlu5 positive allosteric modulators: molecular determinants of MPEP-site interaction crossover.

Authors:  Jason T Manka; Paige N Vinson; Karen J Gregory; Ya Zhou; Richard Williams; Kiran Gogi; Emily Days; Satya Jadhav; Elizabeth J Herman; Hilde Lavreysen; Claire Mackie; José M Bartolomé; Gregor J Macdonald; Thomas Steckler; J Scott Daniels; C David Weaver; Colleen M Niswender; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley; Shaun R Stauffer
Journal:  Bioorg Med Chem Lett       Date:  2012-08-24       Impact factor: 2.823

Review 10.  Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia.

Authors:  Laura E Chavez-Noriega; Hervé Schaffhauser; Una C Campbell
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2002-06
View more
  6 in total

1.  Molecular Insights into Metabotropic Glutamate Receptor Allosteric Modulation.

Authors:  Karen J Gregory; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2015-03-25       Impact factor: 4.436

2.  Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound.

Authors:  Ya Zhou; Chrysa Malosh; Susana Conde-Ceide; Carlos Manuel Martínez-Viturro; Jesus Alcázar; Hilde Lavreysen; Claire Mackie; Thomas M Bridges; J Scott Daniels; Colleen M Niswender; Carrie K Jones; Gregor J Macdonald; Thomas Steckler; P Jeffrey Conn; Shaun R Stauffer; José Manuel Bartolomé-Nebreda; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2015-07-04       Impact factor: 2.823

3.  Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators.

Authors:  Chrysa Malosh; Mark Turlington; Thomas M Bridges; Jerri M Rook; Meredith J Noetzel; Paige N Vinson; Thomas Steckler; Hilde Lavreysen; Claire Mackie; José M Bartolomé-Nebreda; Susana Conde-Ceide; Carlos M Martínez-Viturro; María Piedrafita; M Rosa Sánchez-Casado; Gregor J Macdonald; J Scott Daniels; Carrie K Jones; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Shaun R Stauffer
Journal:  Bioorg Med Chem Lett       Date:  2015-10-09       Impact factor: 2.823

4.  The twin drug approach for novel nicotinic acetylcholine receptor ligands.

Authors:  Isabelle Tomassoli; Daniela Gündisch
Journal:  Bioorg Med Chem       Date:  2015-06-20       Impact factor: 3.641

Review 5.  Allosteric Molecular Switches in Metabotropic Glutamate Receptors.

Authors:  Zoltán Orgován; György G Ferenczy; György M Keserű
Journal:  ChemMedChem       Date:  2020-08-25       Impact factor: 3.466

Review 6.  The Role of mGlu Receptors in Hippocampal Plasticity Deficits in Neurological and Psychiatric Disorders: Implications for Allosteric Modulators as Novel Therapeutic Strategies.

Authors:  Rebecca K Senter; Ayan Ghoshal; Adam G Walker; Zixiu Xiang; Colleen M Niswender; P Jeffrey Conn
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.